Skip to main content

Peer Review reports

From: Real-World Safety and Efficacy of 156 U – 195 U OnabotulinumtoxinA in Adults With Chronic Migraine: Results From the REPOSE Study

Original Submission
24 Sep 2024 Submitted Original manuscript
3 Oct 2024 Author responded Author comments - Fayyaz Ahmed
7 Oct 2024 Author responded Author comments - Fayyaz Ahmed
Resubmission - Version 2
3 Oct 2024 Submitted Manuscript version 2
16 Oct 2024 Reviewed Reviewer Report - Wim Mulleners
30 Oct 2024 Reviewed Reviewer Report
9 Dec 2024 Author responded Author comments - Fayyaz Ahmed
Resubmission - Version 3
9 Dec 2024 Submitted Manuscript version 3
11 Dec 2024 Author responded Author comments - Fayyaz Ahmed
Resubmission - Version 4
11 Dec 2024 Submitted Manuscript version 4
19 Dec 2024 Reviewed Reviewer Report - Wim Mulleners
19 Dec 2024 Reviewed Reviewer Report
31 Jan 2025 Author responded Author comments - Fayyaz Ahmed
Resubmission - Version 5
31 Jan 2025 Submitted Manuscript version 5
3 Feb 2025 Author responded Author comments - Fayyaz Ahmed
Resubmission - Version 6
3 Feb 2025 Submitted Manuscript version 6
4 Feb 2025 Author responded Author comments - Fayyaz Ahmed
Resubmission - Version 7
4 Feb 2025 Submitted Manuscript version 7
5 Feb 2025 Author responded Author comments - Fayyaz Ahmed
Resubmission - Version 8
5 Feb 2025 Submitted Manuscript version 8
7 Feb 2025 Author responded Author comments - Fayyaz Ahmed
Resubmission - Version 9
7 Feb 2025 Submitted Manuscript version 9
10 Feb 2025 Author responded Author comments - Fayyaz Ahmed
Resubmission - Version 10
10 Feb 2025 Submitted Manuscript version 10
11 Feb 2025 Author responded Author comments - Fayyaz Ahmed
Resubmission - Version 11
11 Feb 2025 Submitted Manuscript version 11
Publishing
14 Feb 2025 Editorially accepted
6 May 2025 Article published 10.1186/s12883-025-04087-7

You can find further information about peer review here.

Back to article page